Mesoblast (NASDAQ:MESO) has earned an average rating of “Hold” from the eight brokerages that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $15.00.
Several equities research analysts have weighed in on MESO shares. Credit Suisse Group downgraded Mesoblast from a “neutral” rating to an “underperform” rating and set a $6.00 price target for the company. in a report on Thursday, March 22nd. Maxim Group set a $14.00 price target on Mesoblast and gave the stock a “buy” rating in a report on Thursday, February 22nd. Cantor Fitzgerald set a $20.00 price target on Mesoblast and gave the stock a “buy” rating in a report on Tuesday, January 16th. Finally, Zacks Investment Research cut Mesoblast from a “buy” rating to a “hold” rating in a research note on Tuesday, January 23rd.
NASDAQ MESO traded up $0.05 during trading on Friday, hitting $5.54. The company’s stock had a trading volume of 24,536 shares, compared to its average volume of 57,883. The company has a market cap of $528.30, a PE ratio of -5.71 and a beta of 1.95. Mesoblast has a fifty-two week low of $4.74 and a fifty-two week high of $12.50.
Mesoblast (NASDAQ:MESO) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.09. The business had revenue of $13.40 million during the quarter, compared to the consensus estimate of $0.34 million. Mesoblast had a negative return on equity of 9.78% and a negative net margin of 188.83%. analysts expect that Mesoblast will post -0.49 EPS for the current year.
A hedge fund recently bought a new stake in Mesoblast stock. Princeton Capital Management LLC purchased a new stake in shares of Mesoblast (NASDAQ:MESO) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 124,022 shares of the company’s stock, valued at approximately $724,000. Princeton Capital Management LLC owned approximately 0.13% of Mesoblast at the end of the most recent quarter. Institutional investors and hedge funds own 2.85% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Mesoblast (MESO) Given Consensus Rating of “Hold” by Analysts” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/25/mesoblast-meso-given-consensus-rating-of-hold-by-analysts.html.
Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.